| P2093 | author name string | Ying Liu | |
| | Xiaodong Jiao | |
| | Ke Liu | |
| | Zhan Wang | |
| | Miaomiao Wang | |
| | Jiejun Wang | |
| | Yuan-Sheng Zang | |
| | Wenzheng Fang | |
| P2860 | cites work | PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives | Q38710627 |
| | Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis? | Q38780033 |
| | Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies | Q38793867 |
| | Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers | Q38838077 |
| | Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice | Q39175791 |
| | Acute L-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells. | Q40161425 |
| | Regulatory and molecular aspects of mammalian amino acid transport | Q40747714 |
| | Oncogenic regulation of tumor metabolic reprogramming | Q42321596 |
| | High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study | Q43961345 |
| | Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilar cholangiocarcinoma | Q45385818 |
| | 12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway. | Q54255044 |
| | Targeting glutamine transport to suppress melanoma cell growth. | Q54376941 |
| | Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer | Q81413248 |
| | Osteosarcoma | Q84342547 |
| | Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression | Q31123096 |
| | Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer | Q34342897 |
| | Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. | Q34634489 |
| | Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma | Q35249353 |
| | Biology and therapeutic advances for pediatric osteosarcoma | Q35841976 |
| | PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma | Q36292690 |
| | The prognostic potential and oncogenic effects of PRR11 expression in hilar cholangiocarcinoma | Q36299705 |
| | Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells. | Q37065899 |
| | The etiology of osteosarcoma | Q37705038 |
| | Anti-angiogenesis therapy in cancer: current challenges and future perspectives | Q37994504 |
| | Development of PI3K inhibitors: lessons learned from early clinical trials | Q38080710 |
| | The SLC3 and SLC7 families of amino acid transporters | Q38090767 |
| | Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects | Q38090789 |
| | Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach | Q38592248 |
| | Update on Survival in Osteosarcoma | Q38651549 |
| | Osteosarcoma: A Meta-Analysis and Review of the Literature | Q38668801 |
| | Glutamine transporters in mammalian cells and their functions in physiology and cancer | Q38685207 |
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 78930-78939 | |
| P577 | publication date | 2017-09-05 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Increased SNAT1 is a marker of human osteosarcoma and potential therapeutic target | |
| P478 | volume | 8 | |